XAIR Share Price Performance
US$0
-4.16 (-100.00%)
Price US$0
Fair ValueUS$8.00
Share Pricen/a
Beyond Air, Inc. Stock Price
- 3 Narratives written by author
- 2 Comments on narratives written by author
- 20 Fair Values set on narratives written by author
XAIR Community Narratives
AN
Fair Value
·Fair Value US$8 94.5% undervalued intrinsic discount
XAIR: Global Network Expansion Will Drive Long-Term Market Presence
0users have liked this narrative
0users have commented on this narrative
16users have followed this narrative
AN
Fair Value
·Fair Value US$2 78.0% undervalued intrinsic discount
Slow Hospital Onboarding Will Constrain Revenue With Eventual Recovery
0users have liked this narrative
1users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value US$14 96.9% undervalued intrinsic discount
Aging Populations And Precision Medicine Will Reshape Respiratory Care
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
XAIR: Global Network Expansion Will Drive Long-Term Market Presence
Beyond Air is pushing its LungFit respiratory device into more hospitals worldwide through new partners and big U.S. buying networks, aiming to turn early traction into steadier, repeat business. The catch is it’s still burning cash and depends heavily on this one platform, so any product delays or slower adoption could force more fundraising and slow the story.Read more
AN
US$8
94.5% undervalued intrinsic discount
Fair Value
Profit Margin
12.11%
Future PE
21.51x
Price in 2029
US$10.59
Slow Hospital Onboarding Will Constrain Revenue With Eventual Recovery
Key Takeaways Slow onboarding in hospitals and regulatory hurdles may significantly restrict revenue growth and the ability to capitalize on expanding market access. Heavy reliance on a single core product and growing competition from advanced medtech firms increase both revenue concentration risk and margin pressure.Read more
AN
US$2
78.0% undervalued intrinsic discount
Fair Value
Profit Margin
12.79%
Future PE
4.38x
Price in 2029
US$2.65
Aging Populations And Precision Medicine Will Reshape Respiratory Care
Key Takeaways Accelerating hospital access and international partnerships could significantly outpace current revenue expectations, fueling rapid global growth opportunities. Recurring revenue from consumables and unique technology positions Beyond Air for strong earnings growth and strategic advantage in a transforming healthcare market.Read more
AN
US$14
96.9% undervalued intrinsic discount
Fair Value
Profit Margin
4.68%
Future PE
40.79x
Price in 2028
US$17.15
Trending Discussion
Recently Updated Narratives
AN
XAIR: Hospital Access Expansion And Reverse Split Plans Will Support Future Upside
Fair Value: US$8 94.5% undervalued intrinsic discount
16 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
XAIR: Later FDA Decision Will Still Drive Key Future Inflection
Fair Value: US$2 78.0% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
AN
Aging Populations And Precision Medicine Will Reshape Respiratory Care
Fair Value: US$14 96.9% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Beyond Air, Inc. Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
- -2.31
- 3.28%
- -432.99%
- 354.9%
About XAIR
- Founded
- 2011
- Employees
- 54
- CEO
- WebsiteView website
Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company. It operates through Beyond Air, Beyond Cancer, and NeuroNos segments. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO to treat viral lung infections, such as viral community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM). In addition, the company develops ultra-high concentration NO (UNO) that is in Phase 1 clinical trial to treat solid tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.
